Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia

Keyphrases

• Pharmacogenomics 100%
• Schizophrenia Treatment 100%
• Tolcapone 100%
• Catechol-O-methyltransferase Polymorphism 100%
• Cognitive Function 66%
• Cognitive Symptoms 66%
• Dopaminergic Pathway 66%
• Catechol-O-methyltransferase 66%
• Prefrontal Dopamine 66%
• Schizophrenia 33%
• Antipsychotics 33%
• Targeted Treatment 33%
• Prefrontal Cortex 33%
• Hypothesis-driven 33%
• Negative Symptoms 33%
• Negative Symptoms of Schizophrenia 33%
• Catechol-O-methyltransferase Inhibitors 33%
• Prefrontal Function 33%
• Primary Problem 33%
• Genotype-specific 33%

Medicine and Dentistry

• Pharmacogenomics 100%
• Methyltransferase 100%
• Treatment of Schizophrenia 100%
• Tolcapone 100%
• Negative Syndrome 50%
• Cognition 50%
• Schizophrenia 50%
• Dopamine 50%
• Targeted Therapy 25%
• Prefrontal Cortex 25%
• DNA Polymorphism 25%
• Methyltransferase Inhibitor 25%
• Diseases 25%

Neuroscience

• Treatment of Schizophrenia 100%
• Methyltransferase 100%
• Tolcapone 100%
• Cognitive Function 40%
• Negative Syndrome 40%
• Dopamine 40%
• Schizophrenia 40%
• DNA Polymorphism 20%
• Prefrontal Cortex 20%